BioCentury | Aug 31, 2020
Regulation

FDA should maintain ‘social distance’ from the White House

One of the most important public health tools to emerge this year is the concept of social distance. Its benefits aren’t limited to outdoor dining or supermarket checkout lines; they extend to interactions...
BioCentury | Aug 25, 2020
Regulation

Politics & plasma: a BioCentury podcast

Ex-FDA officials are mixed on the merits of an agency decision to grant an EUA for COVID-19 convalescent plasma, but there is widespread agreement that the process was marred by political posturing, including statements by...
BioCentury | Aug 24, 2020
Politics, Policy & Law

Angered by NIH’s Collins, Trump misfires and hits FDA Commissioner Hahn

President Donald Trump’s recent attacks on FDA were prompted by Trump’s anger at NIH Director Francis Collins for delaying authorization of COVID-19 convalescent plasma, individuals who have been in close touch with the White House...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Nov 26, 2019
Politics & Policy

Pioneering FDA commissioner Frank Young dies at 88

Frank Young, who served as FDA Commissioner from 1984 to 1989, a pivotal and tumultuous era in drug regulation, died Nov. 24 at age 88. He was diagnosed last week with B Cell Lymphoma. Former...
BioCentury | Oct 7, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
BioCentury | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
BioCentury | May 10, 2019
Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

While the gut microbiome has attracted wide attention for its influence on anti-tumor immunity, a growing body of research suggests microbes living in the tumor itself may play even broader roles in cancer. At least...
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Cell culture experiments suggest inhibiting PARG alone or in combination with Chk1 inhibitors could help treat ovarian cancer. In three human ovarian cancer cell lines, a tool compound PARG...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
Items per page:
1 - 10 of 416